Physician profile
Dee A Fanning
NPI 1205435112
$3,440.71
in general payments reported to CMS, 2019-2025
21 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.95 · 2023: $743 · 2024: $1,107 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.60 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $479.81 | 2023-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $282.76 | 2023-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $243.24 | 2022-2025 | Dupixent |
| Pfizer INC. | $173.63 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $167.10 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $154.92 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $153.15 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $149.26 | 2024-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $125.76 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $121.55 | 2022-2024 | Dificid, Zinplava |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.67 | 2024-2025 | Xifaxan |
| Celltrion USA INC. | $57.58 | 2024-2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $57.20 | 2023 | |
| Lilly USA, LLC | $49.38 | 2024-2025 | Omvoh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $33.62 | 2023 | Talicia |
| Intercept Pharmaceuticals, INC. | $28.00 | 2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $20.44 | 2023 | Rebyota |
| Gilead Sciences, INC. | $14.74 | 2024 | |
| Celgene Corporation | $14.43 | 2023 | Zeposia |
| Novo Nordisk INC | $13.87 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dee Fanning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.